Community Research and Development Information Service - CORDIS

Seventh Framework Programme (FP7)

FP7 Home
Cooperation
Ideas
People
Capacities
Euratom
JRC
© shutterstock© shutterstock
JRC Ideas Cooperation FP7
Euratom Capacities People
About | What's New? | Sitemap
Find a project

Angiogenesis-inducing bioactive and bioresponsive scaffolds in tissue enginering (ANGIOSCAFF)

Funded under 7th FWP (Seventh Framework Programme)

Research area: NMP-2007-2.3-1 Highly porous bioactive scaffolds favouring angiogenesis for tissue engineering

Coordinator
Contact Person: Name: MATTSSON, Christina (Ms.)
Tel: +41-21-6939668
Fax: +41-21-6939665
Email: Contact
Organisation: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Bâtiment CE-3.316 Station 1
SWITZERLAND

Project description

Angiogenesis underlies almost all biological processes of morphogenesis, including those in tissue repair and regeneration. Physiological angiogenesis is controlled by a complex interplay between cells and their environment: the extracellular matrix (ECM) provides signalling via numerous ECM adhesion molecules and growth factors bound to ECM polysaccharide components; and cells locally degrade and remodel the ECM to create pores into which angiogenic endothelial cells migrate.

This observation, that physiological angiogenesis proceeds in response to solid-phase cues motivates our approach, namely creating bioactive resorbable materials as scaffolds that contain bound molecular signals to induce physiological angiogenesis in situations of tissue repair and regeneration. In some of our scaffold materials, porosity is inherent by virtue of fabrication, and in others porosity is created by cell-associated proteolysis as it is in physiological angiogenesis. All materials will be designed so as to be injectable or implantable into the human body. In some work, the final injectable/implantable material will comprise only materials and bioactive biomolecular signals, and in other cases it will also comprise cells.

Thus, the concept of ANGIOSCAFF is to create materials that are bioresponsive (to environmental signals including pH and redox potential, and to cellular signals such as proteases), that are bioactive (by virtue of bound peptide or recombinant protein adhesion ligands and bound and releasable growth factors), and that are capable of carrying cellular therapeutics. To realize ANGIOSCAFF, we have assembled a team comprising both industrial and academic expert groups in biomaterials design and development, experts in the science and application of angiogenesis, in imaging in animal models, and in applications demanding biomaterials-based, angiogenesis-demanding tissue engineering therapies, including repair of bone, skin, cardiac muscle, skeletal muscle and nerve.


Project details
Project Acronym: ANGIOSCAFF
Project Reference: 214402
Start Date: 2008-12-01
Duration: 48 months
Project Cost: 15.62 million euro
Contract Type: Large-scale integrating project
End Date: 2012-11-30
Project Status: Execution
Project Funding: 11.63 million euro

Participants
BAXTER INNOVATIONS GMBH AUSTRIA
FONDAZIONE MULTIMEDICA ONLUS ITALY
UNIVERSITAET ZU KOELN GERMANY
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY. ISRAEL
UNIVERSITAETSSPITAL BASEL SWITZERLAND
INTERCYTEX LTD UNITED KINGDOM
SMITH & NEPHEW UK LIMITED UNITED KINGDOM
FONDAZIONE PARCO BIOMEDICO SAN RAFFAELE ITALY
BIORIGEN S.R.L. ITALY
BIO-HYOS AB SWEDEN
BAYER INNOVATION GMBH GERMANY
LUDWIG BOLTZMANN GESELLSCHAFT OSTERREICHISCHE VEREINIGUNG ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG AUSTRIA
FUNDACIÓ PRIVADA INSTITUT DE BIOENGINYERIA DE CATALUNYA SPAIN
KUROS BIOSURGERY AG SWITZERLAND
MILTENYI BIOTEC GMBH GERMANY
NEURONOVA AB SWEDEN
LEIBNIZ-INSTITUT FUR POLYMERFORSCHUNG DRESDEN E.V. GERMANY
ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO ITALY
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF GERMANY
DANDO AND COLUCCI LLC UNITED KINGDOM
UNIVERSITAET ZUERICH SWITZERLAND
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS SPAIN
UPPSALA UNIVERSITET SWEDEN
EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRICH SWITZERLAND
JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN GERMANY
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE UNITED KINGDOM
IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE ITALY
THE UNIVERSITY OF NOTTINGHAM UNITED KINGDOM
Record Control Number: 88874
Update Date: 2009-10-12 10:32:14.0

Go back - Previous project - Next project

CORDIS RTD-PROJECTS / © European Communities.